Drug intelligence / Profile preview

BST-104 (Blackstone Therapeutics)

Development stage: Preclinical
Lead developer: Blackstone Therapeutics
Modality: Small Molecules

Overview

BST-104 is a preclinical-stage small molecule cannabinoid drug candidate being developed by Blackstone Therapeutics. It is currently under investigation for its therapeutic potential in treating pancreatic cancer, lung cancer, and neuropsychiatric conditions such as depression and anxiety. As a cannabinoid-based therapy, BST-104 is designed to interact with the endocannabinoid system to modulate biological pathways relevant to oncology and mental health. The specific molecular targets and precise mechanism of action for BST-104 have not been publicly disclosed, but the compound represents a key asset in Blackstone Therapeutics' research and development pipeline focused on leveraging cannabinoid pharmacology for complex diseases.

Beyond the preview

Go deeper on BST-104 (Blackstone Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BST-104 (Blackstone Therapeutics).

Explore the full profile